Major research papers from NEJM in 2023
January 25, 2024 by dr s venkatesan
Here is a pleasant surprise, a collectors issue of NEJM year book 2023, is made available free (even for a non subscribers in its website) .It is fascinating to know how fast the Internal medicine has grown. For the busy cardiologists, this will a be refreshing reminder, that there are other important organs and specialties do exist in medicine , with equal breakthroughs and Innovations.
It is indeed an amazing , whirlwind tour of medicine for all those who see medical science as single holistic specialty. It has articles, ranging from from simple clinical studies on postpartum hemorrhage (E-MOTIVE study) from deep inside Africa by Melinda Gate foundation, to Dupilumab for COPD, a stunning monoclonal antibody inhibitor of IL-4 for COPD exacerbations. Shortening tuberculosis treatment with a strategy involving initial treatment with an 8-week Bedaquiline-linezolid regimen (TRUNCATE-TB study) is also a revelation.
Of-course, the mandatory cardiac topics do find a prominent place including the currently omnipresent drug GLP agonist Semaglutide for HFpEF (STEP-HFpEF study). Baxdrostat, an Aldosterone synthase antagonist for treatment-resistant Hypertension, appears promising (BrigHTN).
Final message
However, the crowning glory among all articles appear towards the end of the document, titled Combating misinformation as a core Function of Public Health.
Let me share the link to this PDF document here. Hope it allows open access and there are no copyright issues. Notable articles of 2023 from NEJM .
Posted in Uncategorized | Tagged 2023 review articles, acc aha esc guidlines, an Aldosterone synthase antagonist for Treatment-Resistant Hypertension, Baxdrostat, bmj, E MOTIVE STUDY PPH, lancet, nejm, Of-course, semaglutide, TRUNCATE TB |
- The Renal Warrior Project. Join Now
- Source: https://drsvenkatesan.com/2024/01/25/major-research-papers-from-nejm-in-2023/